Says therapeutic portfolio ‘demonstrating very strong momentum’ into 2025. Says making “significant progress” in R&D efforts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie says ‘very pleased’ with progress in 2024, sees ‘strong growth’ in 2025
- ABBV Earnings: AbbVie Rallies Alongside Q4 Beats
- Morning Movers: Apple and Exxon higher following quarterly earnings
- AbbVie reports Q4 adjusted EPS $2.16, consensus $2.26
- AbbVie sees FY25 adjusted EPS $12.12-$12.32, consensus $12.13